Faculty Opinions recommendation of KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature（2023）
关键词
pembrolizumab,early stage nsclc,chemotherapy,placebo,faculty opinions recommendation,double-blind,platinum-based
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要